TNAs, or therapeutic nucleic acids, are nucleic acids or closely related compounds that are used to cure disease. TNAs come in a variety of shapes and sizes, but they all have the same mode of action: sequence specific recognition of endogenous nucleic acids via Watson–Crick base pairing. The growing number of FDA-approved nucleic acid therapies shows that diseases can be treated in vivo by addressing their genetic blueprints. Because they target proteins rather than the underlying reasons, traditional therapies typically have transitory therapeutic results. Nucleic acid treatments, on the other hand, can achieve long-lasting or even curative effects by inhibiting, replacing, or altering genes. However, delivery strategies that improve stability, enable internalisation, and boost target affinity are required for clinical translation. Synthetic biology, systems biology, computational biology, bioinformatics, and nanotechnology, among other fields, have accelerated progress and established a new paradigm for nucleic acids in therapy.
Title : Renewed novel biotech ideas, with bioreactor bioengineering economic impact
Murray Moo Young, University of Waterloo, Canada
Title : Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Limongi Tania, University of Turin, Italy
Title : Bioherbicides for eco-friendly weed management: From fields to commercialization, constraints and solutions for sustainable agriculture
K R Aneja, Kurukshetra University, India
Title : Predicting wound closure and future segmentation masks in wound healing assays
Alfredo De Cillis, Univeristy of Salento, CNR Nanotec, Italy
Title : Utilizing complex coacervation to promote the controlled crystallization of hydrophobic drugs
Anvesha Subramanian, University of Houston, United States
Title : Improving health in over 40,000 patients: The impact of nanomedicine fighting antibiotic resistant infections
Thomas J Webster, Brown University, United States